Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

MYPI2025000192A0Undetermined Publication Date: 2021-10-24F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000192
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-24
Filing Date
2021-04-23
Publication Date
2021-10-24
Patent Text Reader

Abstract

The present invention relates to proteins, particularly antibodies such as anti-CD20 / anti-CD3 bispecific antibodies and anti α-synuclein antibodies, having monogalactosylated (G1) and digalactosylated (G2) glycans. More particular, the present invention relates to galactosylation engineering to generate proteins with improved therapeutic properties, including proteins with increased titer. Further, the invention relates to a cell culture medium and a mammalian cell as well as methods using said cell culture medium and said mammalian cell for producing said proteins. Moreover, the present invention relates to the use of said antibodies as a medicament such as for the treatment of cancer, particularly cancer associated with B-cells, or Parkinson´s disease. [No Suitable Figures]
Need to check novelty before this filing date? Find Prior Art